Universitynof michigan
Oncology
Dr. Max S. Wicha, MD
|
|
Give Review
Wicha works in the field of Oncology. He went to Stanford University School of Medicine. Stanford University School of Medicine is a top medical college. Stanford University School of Medicine is ranked 2/25 in Research/PrimaryCare. He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Redbook Magazine: Top Breast Cancer Doctors", "Elected Member" and "Whos Who in Medicine and Healthcare". Wicha is a published doctor and has 101 publications published. The lastest was: 'A method of limited replication for the efficient in vivo delivery of adenovirus to cancer cells.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Clinical predictors of long-term survival in HER2-positive metastatic breast Cancer.
- Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast Cancer.
- Metabolic plasticity of Cancer stem cells.
- Leptin and Adiponectin Modulate the Self-renewal of Normal Human Breast Epithelial Stem Cells.
- Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.
- Notch Reporter Activity in Breast Cancer Cell Lines Identifies a Subset of Cells with Stem Cell Activity.
- Epithelial-Mesenchymal Plasticity of Breast Cancer Stem Cells: Implications for Metastasis and Therapeutic Resistance.
- Expansion of CTCs from early stage lung Cancer patients using a microfluidic co-culture model.
- A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells.
- Endothelial interleukin-6 defines the tumorigenic potential of primary human Cancer stem cells.
- KRAS and Cancer Stem Cells in APC-Mutant Colorectal Cancer.
- SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast Cancer model.
- Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts.
- Targeting self-renewal, an Achilles' heel of Cancer stem cells.
- Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets.
- Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2.
- Distinct FAK activities determine progenitor and mammary stem cell characteristics.
- HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab.
- Notch pathway activity identifies cells with Cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma.
- Breast Cancer Stem Cells: We've Got Them Surrounded.
- Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors.
- Migratory gene expression signature predicts poor patient outcome: Are Cancer stem cells to blame?
- Cancer Stem Cells--The Evidence Accumulates.
- Targeting Cancer stem cells via dendritic-cell vaccination.
- Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant Breast lesions of Ghanaian women.
- Lin28 and HER2: Two stem cell regulators conspire to drive aggressive breast Cancer.
- Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population.
- MicroRNA93 Regulates Proliferation and Differentiation of Normal and Malignant Breast Stem Cells.
- Antiangiogenic agents: Fueling Cancer's hypoxic roots.
- Breast Cancer stem cells, cytokine networks, and the tumor microenvironment.
- Inflammation and autophagy conspire to promote tumor growth.
- Ablation of breast Cancer stem cells with radiation.
- Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancers Inflammatory Roots.
- Circulating tumor cells: not all detected cells are bad and not all bad cells are detected.
- Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian Cancer stem cells that portend poor patient survival.
- Expression of aldehyde dehydrogenase and CD133 defines ovarian Cancer stem cells.
- Implications of Cancer stem cell theory for Cancer chemoprevention by natural dietary compounds.
- Stemming a tumor with a little miR.
- Breast Cancer stem cells are regulated by mesenchymal stem cells through cytokine networks.
- Endothelial cell-initiated signaling promotes the survival and self-renewal of Cancer stem cells.
- Targeting breast Cancer stem cells.
- Single-marker identification of head and neck squamous cell carcinoma Cancer stem cells with aldehyde dehydrogenase.
- Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast Cancer stem cells.
- CXCR1 blockade selectively targets human breast Cancer stem cells in vitro and in xenografts.
- Aldehyde dehydrogenase 1-positive Cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast Cancer.
- Identification of single chain antibodies to breast Cancer stem cells using phage display.
- Retinoid signaling regulates breast Cancer stem cell differentiation.
- An embryonic stem cell-like signature identifies poorly differentiated lung adenoCarcinoma but not squamous cell Carcinoma.
- Getting to the root of BRCA1-deficient breast Cancer.
- Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.
- Aldehyde dehydrogenase 1 is a marker for normal and Malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.
- HER-2, notch, and breast Cancer stem cells: targeting an axis of evil.
- Tumor-initiating cells and treatment resistance: how goes the war?
- Breast Cancer cell lines contain functional Cancer stem cells with metastatic capacity and a distinct molecular signature.
- Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary Cancer stem/progenitor cells.
- Implications of the Cancer stem-cell hypothesis for breast Cancer prevention and therapy.
- Cancer stem cells: a step toward the cure.
- BRCA1 regulates human mammary stem/progenitor cell fate.
- ALDH1 is a marker of normal and Malignant human mammary stem cells and a predictor of poor clinical outcome.
- Cancer stem cells: implications for Cancer treatment and prevention.
- Breast Cancer stem cells-research opportunities utilizing mathematical modeling.
- Breast Cancer stem cells: the other side of the story.
- Cancer stem cells and metastasis: lethal seeds.
- Hedgehog signaling and Bmi-1 regulate self-renewal of normal and Malignant human mammary stem cells.
- Cancer stem cells: an old idea--a paradigm shift.
- Stem cells in mammary development and carcinogenesis: implications for prevention and treatment.
- Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia.
- New organizational and funds flow models for an academic Cancer center.
- Breast Cancer, stem/progenitor cells and the estrogen receptor.
- In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.
- Prospective identification of tumorigenic breast Cancer cells.
- A bcl-x(S) adenovirus demonstrates therapeutic efficacy in an ascites model of human breast Cancer.
- Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University c...
- A bcl-xS adenovirus selectively induces apoptosis in transformed cells compared to normal mammary cells.
- A novel, conditionally replicative adenovirus for the treatment of breast Cancer that allows controlled replication of E1a-deleted adenoviral vectors.
- Interaction of rat mammary epithelium with extracellular matrix components.
- Blocking basement membrane collagen deposition inhibits the growth of 7,12-dimethylbenzanthracene-induced rat mammary Tumors.
- Extracellular matrix promotes mammary epithelial growth and differentiation in vitro.
- Sensitivity of N-nitrosomethylurea-induced rat mammary Tumors to cis-hydroxyproline, an inhibitor of collagen production.
- Distribution of pemphigus and pemphigoid antigens, laminin, and type IV collagen in corneal epithelium.
- Effects of inhibition of basement membrane collagen deposition on rat mammary gland development.
- Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis.
- Murine granulocytic cell adhesion to bone marrow hemonectin is mediated by mannose and galactose.
- bcl-xs gene therapy induces apoptosis of human mammary Tumors in nude mice.
- Targeting Cancer cell death with a bcl-XS adenovirus.
- Immunolymphoscintigraphy in breast Cancer: evaluation using 131I-labeled monoclonal antibody B72.3.
- A method of limited replication for the efficient in vivo delivery of adenovirus to Cancer cells.
- Unsaturated fatty acid requirements for growth and survival of a rat mammary tumor cell line.
- Hormonal requirements for basement membrane collagen deposition by cultured rat mammary epithelium.
- Basement membrane collagen requirements for attachment and growth of mammary epithelium.
- Effects of free fatty acids on the growth of normal and neoplastic rat mammary epithelial cells.
- cDNA cloning and genomic analysis of a new multigene family sharing common phylogenetic and expression profiles with the laminin receptor gene.
- Posttranscriptional regulation of alpha-casein mRNA accumulation by laminin.
- cDNA cloning and molecular characterization of MSE55, a novel human serum constituent protein that displays bone marrow stromal/endothelial cell-specific expression.
- Genomic analysis of the 67-kDa laminin receptor in normal and pathological tissues: circumstantial evidence for retroposon features.
- Macrophages express a plasma membrane receptor for basement membrane laminin.
- Human neutrophil laminin receptors: activation-dependent receptor expression.
- Extracellular matrix and the hematopoietic microenvironment.
- Haemonectin, a bone marrow adhesion protein specific for cells of granulocyte lineage.
- Role of the cytoskeleton in laminin induced mammary gene expression.
Schools
Stanford University
University Chicago Hosps
National Institute Of Health
Conditions Treated
- Anemia
- Bladder Cancer
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Redbook Magazine: Top Breast Cancer Doctors
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
University of Chicago -
Stanford University School of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1265518138 | |
| NPPES Provider LastName | WICHA | |
| NPPES Provider FirstName | MAX | |
| NPPES Provider ZIPCode | 481095916 | |
| NPPES Provider State | MI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 298.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265518138 |
| Last Name Of The Provider | WICHA |
| First Name Of The Provider | MAX |
| View All |
Similar Doctors
|
|
Dr. Susan G. Urba, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathleen A. Cooney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dean E. Brenner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maha H. Hussain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monika L. Burness, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Moshe Talpaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kemp B. Cease, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer J. Griggs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander T. Pearson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne F. Schott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raymond M. Esper, MD
This Doctor is OpenDoctor Recommended.
|